United States //   News Releases

News Releases

News Releases

Date Title and Summary Additional Formats
Toggle Summary John McDermott Steps Down as Chief Executive Officer of Endologix, Inc.
IRVINE, Calif. --(BUSINESS WIRE)-- Endologix , Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott is stepping down as the Company's Chief Executive Officer. To facilitate a smooth transition, Mr.
View HTML
Toggle Summary Endologix Reports Fourth Quarter and Fiscal Year 2017 Financial Results
IRVINE, Calif. --(BUSINESS WIRE)-- Endologix, Inc. (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the fourth quarter and fiscal year ended December 31, 2017 . "While our top-line performance during the fourth quarter
View HTML
Toggle Summary Endologix, Inc. Completes Patient Enrollment in the ELEVATE IDE Clinical Study
IRVINE, Calif. --(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today the completion of enrollment in the E xpanding Patient Applicability with Po l ymer S e aling O vat ion Alto St e nt Graft (ELEVATE) IDE
View HTML
Toggle Summary Endologix, Inc. to Present at the Leerink Partners 7th Annual Global Healthcare Conference
IRVINE, Calif. --(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John McDermott , Chief Executive Officer, and Vaseem Mahboob , Chief Financial Officer, will present at the Leerink Partners 7 th Annual
View HTML
Toggle Summary Endologix Appoints Greg Morrow as Chief Marketing Officer and Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
IRVINE, Calif. --(BUSINESS WIRE)-- Endologix , Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that it has appointed Greg Morrow as the Company's Chief Marketing Officer, effective immediately. Mr.
View HTML
Toggle Summary Endologix, Inc. to Announce Fourth Quarter and Fiscal Year 2017 Financial Results on February 21, 2018
IRVINE, Calif. --(BUSINESS WIRE)-- Endologix , Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the fourth quarter and fiscal year 2017 after the market close on Wednesday, February 21, 2018 .
View HTML
Toggle Summary Endologix, Inc. to Present at the J.P. Morgan Healthcare Conference
IRVINE, Calif. --(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John McDermott , Chief Executive Officer, and Vaseem Mahboob , Chief Financial Officer, will present at the 36 th Annual J.P.
View HTML
Toggle Summary Endologix, Inc. to Present at the Piper Jaffray 29th Annual Healthcare Conference
IRVINE, Calif. --(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John McDermott , Chief Executive Officer, will present at the Piper Jaffray 29 th Annual Healthcare Conference at 2:50 p.m.
View HTML
Toggle Summary Endologix Reports Third Quarter 2017 Financial Results
IRVINE, Calif. --(BUSINESS WIRE)-- Endologix, Inc. (NASDAQ:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the third quarter ended September 30, 2017 . "Third quarter results were in line with our expectations, despite weather
View HTML
Toggle Summary Endologix Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
IRVINE, Calif. --(BUSINESS WIRE)-- Endologix , Inc. (Nasdaq:ELGX) ("Endologix"), a developer and marketer of innovative treatments for aortic disorders, announced today the grant of inducement equity awards to its newly appointed Chief Operating Officer, John Onopchenko.
View HTML
Toggle Summary Endologix, Inc. to Present at the Stifel 2017 Healthcare Conference
IRVINE, Calif. --(BUSINESS WIRE)-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John McDermott , Chief Executive Officer, and Vaseem Mahboob , Chief Financial Officer, will present at the Stifel 2017 Healthcare
View HTML
Toggle Summary Endologix Appoints John Onopchenko as Chief Operating Officer
IRVINE, Calif. --(BUSINESS WIRE)-- Endologix , Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that it has appointed John Onopchenko as the Company's Chief Operating Officer, effective October 30, 2017 . Mr.
View HTML
Toggle Summary Endologix, Inc. to Announce Third Quarter 2017 Financial Results on November 7, 2017
IRVINE, Calif. --(BUSINESS WIRE)-- Endologix , Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the third quarter of fiscal year 2017 after the market close on Tuesday, November 7, 2017 .
View HTML
Toggle Summary Endologix Receives IDE Approval for the EVAS2 Confirmatory Clinical Study to Evaluate the Nellix® EndoVascular Aneurysm Sealing System
IRVINE, Calif. --(BUSINESS WIRE)-- Endologix , Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that it has received Investigational Device Exemption ("IDE") approval from the United States Food and Drug Administration (" FDA ") to commence
View HTML
Toggle Summary Endologix Announces CE Mark Approval for the Nellix® EndoVascular Aneurysm Sealing System with the Refined Indications for Use
IRVINE, Calif. --(BUSINESS WIRE)-- Endologix, Inc. (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced the CE Mark approval for its Nellix ® EndoVascular Aneurysm Sealing System ("Nellix") with the refined Indications for Use (IFU).
View HTML